Alto and Cencora are collaborating to deliver enhanced patient support services and streamline access to prescribed specialty medications. The collaboration leverages Cencora’s patient support ...

Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York ...

Cencora COR has outperformed the market over the past 10 years by 7.55% on an annualized basis producing an average annual return of 18.31%. Currently, Cencora has a market capitalization of $52. ...

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...